Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700418 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1HPGDFKBP1ATP53 | |
| SCHEMBL26112047 | 0.87 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1HPGDFKBP1ATP53 | |
| SCHEMBL29132593 | 0.87 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1HPGDFKBP1ATP53 | |
| SCHEMBL15570547 | 0.86 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1HPGDTP53GAA | |
| SCHEMBL17374329 | 0.86 | CHRNB2 (0.39) | SMN1; SMN2ALDH1A1FKBP1A | |
| SCHEMBL3652002 | 0.85 | MEN1 (0.40) | ALDH1A1GAAMEN1KMT2APPM1B | |
| SCHEMBL18982926 | 0.85 | FKBP1A (0.35) | FKBP1ATHRATHRB | |
| SCHEMBL25241823 | 0.84 | FKBP1A (0.35) | FKBP1ATHRATHRB | |
| SCHEMBL15768338 | 0.84 | LMNA (0.43) | SMN1; SMN2ALDH1A1FKBP1AMEN1KMT2A | |
| SCHEMBL1148059 | 0.84 | LMNA (0.43) | SMN1; SMN2ALDH1A1FKBP1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673881-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230104155-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-04-06 | — | — | US | disclosed |
| US-11174244-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3448838-B1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20200339536-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2020-10-29 | — | — | US | disclosed |
| US-10703748-B2 | Diazanaphthalen-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-07-07 | — | — | US | disclosed |
| US-10556885-B2 | Isoquinolin-3-YL carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-02-11 | — | — | US | disclosed |
| US-10508099-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2019-12-17 | — | — | US | disclosed |
| US-10287267-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190127370-A1 | DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-05-02 | — | — | US | disclosed |
| US-8586754-B2 | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130296295-A1 | BCL-2 SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC (US) | 2013-11-07 | — | — | US | disclosed |
| EP-2507229-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011068561-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| US-7888359-B2 | Cyclohexyl or piperidinyl carboxamide antibiotic derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-02-15 | — | — | US | disclosed |
| US-20100298321-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2001478-B1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20090105232-A1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-04-23 | — | — | US | disclosed |
| EP-2001478-A1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007107965-A1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296295-A1 | BCL-2 SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | SMN1; SMN2 1906/4885ALDH1A1 4137/4885HPGD 802/4885 |
| US-10556885-B2 | Isoquinolin-3-YL carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | SMN1; SMN2 3783/4885ALDH1A1 4102/4885HPGD 2311/4885 |
| US-20190127370-A1 | DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DKK1, WNT1 | SMN1; SMN2 3444/4885ALDH1A1 3626/4885HPGD 3204/4885 |
| US-11673881-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | SMN1; SMN2 3783/4885ALDH1A1 4102/4885HPGD 2311/4885 |
| US-20200339536-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK3, DYRK1B | SMN1; SMN2 3783/4885ALDH1A1 4102/4885HPGD 2311/4885 |
| US-10508099-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | SMN1; SMN2 3783/4885ALDH1A1 4102/4885HPGD 2311/4885 |
| US-10287267-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | SMN1; SMN2 3783/4885ALDH1A1 4102/4885HPGD 2311/4885 |
| US-20230104155-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK3, DYRK1B | SMN1; SMN2 3783/4885ALDH1A1 4102/4885HPGD 2311/4885 |
| US-20100298321-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | SMN1; SMN2 2213/4885ALDH1A1 4308/4885HPGD 835/4885 |
| US-11174244-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | SMN1; SMN2 3783/4885ALDH1A1 4102/4885HPGD 2311/4885 |
| US-20090105232-A1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | CBR3, RXFP4, ODC1 | SMN1; SMN2 4566/4885ALDH1A1 3639/4885HPGD 3678/4885 |
| US-10703748-B2 | Diazanaphthalen-3-yl carboxamides and preparation and use thereof | DYRK1A, DKK1, WNT1 | SMN1; SMN2 3444/4885ALDH1A1 3626/4885HPGD 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.